



**RELATIONSHIP OF PLANTER PRESSURE AND  
GLYCEMIC CONTROL IN TYPE 2 DIABETIC  
PATIENTS WITH AND WITHOUT NEUROPATHY**

Thesis

Submitted for partial fulfillment of Master Degree in Endocrinology and  
Metabolism

By

**Amr Hazem Saad Amer**

(M.B.B.Ch.)

Supervised By

**Prof. Dr. MOHAMED REDA HALAWA**

Professor of Endocrinology and Metabolism

Faculty of Medicine - Ain Shams University

**Dr. YARA MOHAMED EID**

Assistant Professor of Endocrinology and Metabolism

Faculty of Medicine - Ain Shams University

**Dr. RANA AHMED ELHILALY**

Assistant Professor of Physical medicine, Rheumatology, and  
Rehabilitation

Faculty of Medicine - Ain Shams University

Faculty of Medicine

Ain Shams University

2016

بِسْمِ اللَّهِ الرَّحْمَنِ الرَّحِيمِ

{ وَأَنْزَلَ اللَّهُ عَلَيْكَ الْكِتَابَ وَالْحِكْمَةَ وَعَلَّمَكَ مَا

لَمْ تَكُنْ تَعْلَمُ وَكَانَ فَضْلُ اللَّهِ عَلَيْكَ عَظِيمًا }

صدق الله العظيم

سورة النساء - آية 113

## **Acknowledgment**

*First and foremost, I thank **ALLAH**, the most Gracious and the most Merciful, for fulfilment this work.*

*Words do fail me when I come to express my indebtedness and profound gratitude to **Prof. Dr. MOHAMED REDA HALAWA**, Professor of Endocrinology and Metabolism, Faculty of Medicine, Ain Shams University, who guided this work and whenever I was in need. His patience, close supervision and constant encouragement throughout this work are beyond my words of thanks.*

*Special thanks and deepest gratitude to **Dr. YARA MOHAMED EID**, Assistant Professor of endocrinology and metabolism, Faculty of Medicine, Ain Shams University, for dedicating so much of his precious time and effort to complete this work.*

*Special thanks and deepest gratitude to **Dr. RANA AHMED ELHILALY**, Assistant professor of physical medicine, rheumatology, and rehabilitation, Faculty of Medicine, Ain Shams University, for her help, remarkable efforts, continuous support and guidance all the time.*

*Last but not least, I would like to thank **my family** for their continuous and devoted support responsible for every success in my life.*

## **List of Contents**

	Page
• List of Tables	<b>II</b>
• List of Figures	<b>IV</b>
• List of Abbreviations	<b>VII</b>
• Introduction	<b>1</b>
• Aim of the work	<b>2</b>
• Chapter (1): Diabetic Neuropathy	<b>3</b>
• Chapter (2): Biomechanics of diabetic foot	<b>22</b>
• Chapter (3): plantar pressure measurement in diabetes	<b>38</b>
• Subject and methods	<b>52</b>
• Results	<b>62</b>
• discussion	<b>105</b>
• summary	<b>111</b>
• conclusion	<b>113</b>
• recommendations	<b>114</b>
• references	<b>115</b>
• Arabic summary	<b>-----</b>

## **List of Tables**

<b>Table number</b>	<b>Title</b>	<b>Page</b>
<b>1</b>	Demographic data	<b>64</b>
<b>2</b>	Comparison of demographic in Group I (Diabetic neuropathy) and II (Diabetic without neuropathy)	<b>65</b>
<b>3</b>	Comparison of foot deformities in group I (Diabetic neuropathy) and Group II (Diabetic without neuropathy)	<b>69</b>
<b>4</b>	Diabetes duration with age, HbA1c, and BMI	<b>72</b>
<b>5</b>	Diabetes duration in patient with or without deformities	<b>74</b>
<b>6</b>	Comparison of Left foot static plantar pressure (kpa) in Group I and Group II and Group III	<b>77</b>
<b>7</b>	Comparison of right foot static plantar pressure (kpa) in Group I and Group II and Group III	<b>80</b>
<b>8</b>	Comparison of left foot dynamic plantar pressure (kpa) in Group I and Group II and Group III	<b>82</b>
<b>9</b>	Comparison of right foot dynamic plantar pressure (kpa) in Group I and Group II and Group III	<b>85</b>
<b>10</b>	Comparison of left static planter pressure in subgroups according to diabetes duration	<b>87</b>
<b>11</b>	Comparison of right static planter pressure in subgroups according to diabetes duration	<b>89</b>
<b>12</b>	Comparison of left dynamic planter pressure in subgroups according to diabetes duration	<b>91</b>
<b>13</b>	Comparison of right dynamic planter pressure in subgroups according to diabetes duration	<b>93</b>

<b>14</b>	Correlation between left static plantar pressure & Age, BMI, HbA1c, and Diabetes duration in group I (diabetic neuropathy)	<b>96</b>
<b>15</b>	Correlation between right static plantar pressure & Age, BMI, HbA1c, and Diabetes duration in group I (diabetic neuropathy)	<b>97</b>
<b>16</b>	Correlation between left dynamic plantar pressure & Age, BMI, HbA1c, and Diabetes duration in group I (diabetic neuropathy):	<b>98</b>
<b>17</b>	Correlation between right dynamic plantar pressure & Age, BMI, HbA1c, and Diabetes duration in group I (diabetic neuropathy)	<b>99</b>
<b>18</b>	Correlation between left static plantar pressure & Age, BMI, HbA1c, and Diabetes duration in group II (diabetic without neuropathy)	<b>101</b>
<b>19</b>	Correlation between right static plantar pressure & Age, BMI, HbA1c, and Diabetes duration in group II (diabetic without neuropathy)	<b>102</b>
<b>20</b>	Correlation between left dynamic plantar pressure & Age, BMI, HbA1c, and Diabetes duration in group II (diabetic without neuropathy)	<b>103</b>
<b>21</b>	Correlation between right dynamic plantar pressure & Age, BMI, HbA1c, and Diabetes duration in group II (diabetic without neuropathy)	<b>104</b>

## **List of figures**

<b>Figure number</b>	<b>Title</b>	<b>Page</b>
<b>1</b>	diabetic polyneuropathy	<b>12</b>
<b>2</b>	Phlyctenular lesion of plantar aspect	<b>17</b>
<b>3</b>	Foot Structure	<b>23</b>
<b>4</b>	Arches of the Foot	<b>28</b>
<b>5</b>	plantar pressure distribution	<b>40</b>
<b>6</b>	mid-gait approach	<b>45</b>
<b>7</b>	peak pressure plot	<b>46</b>
<b>8</b>	peak plantar pressure	<b>48</b>
<b>9</b>	A static pedobarograph imprint of the normal subject	<b>56</b>
<b>10</b>	Division of foot sole into 10 regions	<b>58</b>
<b>11</b>	Comparison of age in group I (Diabetic neuropathy) and Group II (Diabetic without neuropathy)	<b>66</b>
<b>12</b>	Comparison of BMI in group I (Diabetic neuropathy) and Group II (Diabetic without neuropathy)	<b>67</b>
<b>13</b>	Comparison of HbA1c in group I (Diabetic neuropathy) and Group II (Diabetic without neuropathy)	<b>68</b>
<b>14</b>	Comparison of Diabetes duration in group I (Diabetic neuropathy) and Group II (Diabetic without neuropathy)	<b>69</b>
<b>15</b>	Comparison of foot deformities in group I (Diabetic neuropathy) and Group II (Diabetic without neuropathy)	<b>70</b>
<b>16</b>	Diabetes duration &diabetic neuropathy	<b>71</b>
<b>17</b>	Diabetes duration &diabetic neuropathy	<b>71</b>
<b>18</b>	Comparison of age in both subgroups of diabetes duration	<b>73</b>
<b>19</b>	Comparison of HbA1c in both subgroups of diabetes duration	<b>73</b>

<b>20</b>	Comparison of BMI in both subgroups of diabetes duration	<b>74</b>
<b>21</b>	Diabetes duration in patient with or without deformities	<b>75</b>
<b>22</b>	Sites of measured plantar pressure values	<b>76</b>
<b>23</b>	Comparison of Left foot static plantar pressure (kpa) in Group I and Group II and Group III	<b>78</b>
<b>24</b>	Comparison of right foot static plantar pressure (kpa) in Group I and Group II and Group III	<b>81</b>
<b>25</b>	Comparison of left foot static plantar pressure (kpa) in Group I and Group II and Group III	<b>83</b>
<b>26</b>	Comparison of right foot static plantar pressure (kpa) in Group I and Group II and Group III	<b>86</b>
<b>27</b>	Comparison of left static planter pressure in subgroups according to diabetes duration	<b>88</b>
<b>28</b>	Comparison of right static planter pressure in subgroups according to diabetes duration	<b>90</b>
<b>29</b>	Comparison of left dynamic planter pressure in subgroups according to diabetes duration	<b>92</b>
<b>30</b>	Comparison of right dynamic planter pressure in subgroups according to diabetes duration	<b>94</b>



## **List of Abbreviations**

<b>Abbreviation</b>	<b>Meaning</b>
<b>ABIs</b>	Ankle brachial indices
<b>BMI</b>	Body mass index
<b>CGRP</b>	Calcitonin generelated peptide
<b>DM</b>	Diabetes mellitus
<b>DN</b>	Diabetic neuropathy
<b>DNA</b>	Deoxyribonucleic acid
<b>DPN</b>	Diabetic polyneuropathy
<b>Fp</b>	Frontal plane
<b>GRF</b>	Ground reaction force
<b>HbA1c</b>	Glycated hemoglobin
<b>HS</b>	Heel strike
<b>IP</b>	Interphalangeal
<b>KPa</b>	Kilo Pascal
<b>LDDP</b>	Length-dependent diabetic polyneuropathy
<b>LH</b>	Lateral heel
<b>LJM</b>	Limited joint mobility
<b>M1</b>	First metatarsal area
<b>M2</b>	Second metatarsal area
<b>M3</b>	Third metatarsal area
<b>M4</b>	Forth metatarsal area
<b>M5</b>	Fifth metatarsal area
<b>MF</b>	Mid foot area

<b>Abbreviation</b>	<b>Meaning</b>
<b>MH</b>	Medial heel
<b>MTP</b>	Metatarsophalangeal
<b>PAD</b>	Peripheral arterial disease
<b>PDN</b>	Proximal diabetic neuropathy
<b>PPP</b>	Peak plantar pressure
<b>PTI</b>	Pressure-time integral
<b>Sp</b>	Sagittal plane
<b>STP</b>	Stance phase
<b>T1,T2,T3</b>	Toe areas
<b>TO</b>	Toe off
<b>Tp</b>	Transverse plane

### *Introduction*

Diabetes mellitus (DM) is a common metabolic disorder .The most common form of diabetes is type 2 diabetes. These metabolic abnormalities lead to long-term damage of various organs, causing their dysfunction and failure. Diabetes-related micro-vascular complications are responsible for the majority of new cases of blindness, kidney failure, and non-traumatic amputations(*American Diabetes Association 2013*).

Diabetic neuropathy is the most common and troublesome complication of diabetes, leading to the greatest morbidity and mortality and resulting in a huge economic burden for diabetic care (*Vinik et al, 2003*).

Diabetes mellitus is the leading cause of non-traumatic lower limb amputations, with a 15- to 40-fold increase in risk over that of the non-diabetic population (*Turns, 2011*).

Type 2 diabetes mellitus (DM) patients have an elevated risk of plantar ulceration compared to the normal population. The main risk factors for plantar forefoot ulcers are loss of protective sensation due to sensory neuropathy and increased mechanical stress on the sole of the foot. The parameters of plantar pressure, length of contact time and pressure-time integral (PTI) were determined by pedography at defined foot regions (*Sauseng et al, 1999*).

***Aim of the work***

To examine Relationship of Planter Pressure and Glycemic Control in Type2 Diabetic Patients with and without Neuropathy.

## Diabetic Neuropathy

Diabetes mellitus is the most frequent cause of neuropathy worldwide and an increasing load in many developing countries where obesity and type2 diabetes are becoming more common. Most clinical manifestations of diabetic neuropathy were recognized during the second half of the 19th century, but facts on the pathology of the different patterns of diabetic neuropathies have recently become available, with unpredictable findings of inflammatory lesions in focal diabetic neuropathies. Type 2 diabetes is the most frequent type of diabetes. About 90–95% of population with diabetes have type 2, and one third of them have not been discovered (*Aboderin et al., 2002*).

Type2 diabetes is usually part of a metabolic syndrome that consists of obesity, elevated blood pressure, and high levels of blood lipids (*Kaur, 2014*).

Diabetes mellitus can be described as a “syndrome of abnormal carbohydrate metabolism with acute metabolic complications and chronic vascular, neurological, and orthopedic complications disturbing most organ systems” .It is a main cause of blindness ,renal disease, heart ,peripheral vascular disease ,and lower limb amputation .Diabetes can have severe complications such as hyperglycemia, ketoacidosis, diabetic neuropathy, retinopathy, nephropathy, peripheral vascular disease and lower limb ulcers. Research has demonstrated ethnic inequality in the prevalence of different diabetic complications such as foot ulcerations (*Schie et al., 2001*).

Diabetic neuropathy (DN) is the most frequent and annoying complication of diabetes mellitus (DM), leading to the greatest morbidity and mortality and giving rise to a huge economic trouble for diabetes care, of persons with diabetes, 2-3% develop a foot ulcer annually, while the lifetime incidence rate is 15% (*Stockl et al., 2004*).

It is the most frequent form of neuropathy in the developed countries of the world, explains more hospitalizations than all the other diabetic complications combined, and causes 50% to 75% of non traumatic amputations (*Vuorisalo et al., 2009*).

DN is a set of clinical syndromes that involve specific areas of the nervous system, singly or combined. It may be silent and go undiscovered while exercising its damages; or it may present with clinical symptoms and signs that, although nonspecific and dangerous with slow progression, also resemble those seen in many other diseases. DN is, accordingly, diagnosed by exclusion. Unluckily both endocrinologists and non endocrinologists have not been prepared to recognize the condition, and even when DN is symptomatic, less than one-third of physicians detect the cause or discuss this with their patients (*Herman and Kennedy, 2005*).

### ***CLINICAL ASPECTS OF DIABETIC NEUROPATHY***

More than 80% of patients with clinical diabetic neuropathy have a symmetrical form. In most situations, distal symmetrical polyneuropathy is a sensory neuropathy with distal motor involvement measurable only by electromyography, except in the most serious forms (*Said et al., 2007*).

**CLASSIFICATION**

Diabetic neuropathy is classified into definite clinical syndromes. A typical set of symptoms and signs exist for each syndrome, depending on the component of the peripheral nervous system that is damaged. The most frequently detected neuropathies include:

- Distal symmetric polyneuropathy
- Autonomic neuropathy
- Thoracic and lumbar nerve root disease, causing polyradiculopathies
- Individual cranial and peripheral nerve affection causing focal mononeuropathies, especially disturbing the oculomotor nerve (cranial nerve III) and the median nerve.
- Asymmetric involvement of multiple peripheral nerves, resulting in a mononeuropathy multiplex (*Happichet et al., 2007*)

**PATHOGENESIS OF DIABETIC NEUROPATHIES**

Causative elements include persistent hyperglycemia, microvascular insufficiency, oxidative and nitrosative stress (the reaction of body tissues to nitric oxide, nitrous oxide at levels greater than can be neutralized) defective neurotropism, and autoimmune-mediated nerve destruction (*Vinik et al., 2006*).

However, DN is a heterogeneous group of conditions with widely fluctuating pathology, indicating differences in pathogenic mechanisms for the different clinical syndromes. Recognition of the clinical homolog of these pathologic processes is the first step in achieving the suitable form of intervention (*Yasuda, 2013*).